1. Weiden PJ et al. Psychiatr Serv, 1995; 46: 1049-1054
2. Morken G et al. BMC Psychiatry, 2008; 8: 32-38
Notes to editors:
Zysis is a privately-owned specialty pharmaceutical company optimising therapies for disorders of the central nervous system (CNS). Zysis has reformulated aripiprazole, an effective antipsychotic molecule, to provide a patent-protected, sustained-release, once-weekly maintenance phase therapy in oral tablet form to improve clinical outcomes in schizophrenia and bipolar disorder therapy. Formulation development / initial Phase I studies have been successfully completed and the Phase II clinical programme has been established. Zysis is currently seeking funding to progress the phase II study either through licensing or by raising finance.
About LAO Aripiprazole Once Weekly
LAO Aripiprazole Once Weekly with medically supervised dosing is intended to reduce relapse rate in the population of schizophrenic and bipolar patients who require approaches to increase adherence but who are not ready yet for the highly invasive and extremely expensive option of the LAIs. The ability to achieve oral once weekly dosing for aripiprazole comes from a combination of sustained release technologies; long drug plasma half-life; and the very slow disassociation of drug from the D2 receptors in the brain which appears to be unique to this anti-psychotic. LAO and LAI products are highly synergistic in the market and provide a broader range of options for use in improving adherence, dependent on severity of the condition and relapse history of the patients.
For further information, please contact:
, Chairman Tel: +44-1798-831278
Tel: +44-20-3440-5653 Email: